Alector cuts 11% of workforce as it doubles down on late-stage neuro programs partnered with GSK, AbbVie
A month after revealing plans to concentrate on its late-stage immuno-neurology pipeline, Alector is trimming its headcount by 11%.
The layoffs will impact around 30 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.